Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 277 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hydrocortisone Sodium Succinate Clear all
Completed Phase 4 Interventional Results available

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

NCT03635957
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis, Infusion Reaction (IR) Prophylaxis, Folic Acid
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 14, 2026, 10:32 AM EDT
Terminated Phase 1 Interventional Results available

Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms

NCT02846883
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
1 million MSCs/kg, 3 million MSCs/kg, Placebo
Biological · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 3 Interventional

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

NCT05299554
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
16 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

NCT05675410
View directory record Official record
Conditions
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 60 Years
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
402
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 297 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Recruiting Phase 2 Interventional

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

NCT06895473
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Biospecimen Collection, Cytarabine, Lumbar Puncture, Methotrexate, Therapeutic Hydrocortisone
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

NCT00519818
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency, Adrenogenital Syndrome
Interventions
Chronocort, Cortef
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

NCT00133991
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Filgrastim, Rituximab, Cyclophosphamide, Cytarabine, Methotrexate, Prednisone, Hydrocortisone, Vincristine, Leucovorin
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
30 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 14, 2026, 10:32 AM EDT
Recruiting Phase 2 Interventional

Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma

NCT07763210
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
Interventions
Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide, Axicabtagene Ciloleucel, Brexucabtagene Autoleucel
Drug · Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression

NCT02837432
View directory record Official record
Conditions
Depression
Interventions
Hydrocortisone acetate, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Not applicable Interventional

A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis

NCT01675232
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Soak and smear, Dry Smear
Other
Lead sponsor
Yale University
Other
Eligibility
2 Weeks to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 14, 2026, 10:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

NCT00536991
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Calcitriol, Ketoconazole, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Hydrocortisone
Dietary Supplement · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis

NCT04943289
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
DUOC-01
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Recruiting Phase 1 Interventional

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT06177067
View directory record Official record
Conditions
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions
Revumenib, Venetoclax, Azacitidine, intrathecal (IT) chemotherapy, Cytarabine, Methotrexate
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
San Diego, California • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Terminated Early Phase 1 Interventional

Fludrocortisone for Sudden Hearing Loss

NCT01186185
View directory record Official record
Conditions
Hearing Loss, Sensorineural
Interventions
Fludrocortisone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 14, 2026, 10:32 AM EDT
Active, not recruiting Phase 2 Interventional

Seal, Stopping Eczema and Allergy Study

NCT03742414
View directory record Official record
Conditions
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Combination Product · Other
Lead sponsor
Kari Nadeau, MD, PhD
Other
Eligibility
1 Week to 12 Weeks
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Terminated Phase 4 Interventional

Adrenal Insufficiency in Septic Shock

NCT00842933
View directory record Official record
Conditions
Septic Shock, Acute Adrenal Insufficiency
Interventions
Corticosteroid
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 14, 2026, 10:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT05761171
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Month to 6 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

NCT03194932
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 2 Interventional

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

NCT00002865
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 14, 2026, 10:32 AM EDT
Terminated Phase 2 Interventional

A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer

NCT00006371
View directory record Official record
Conditions
Prostate Cancer
Interventions
aminoglutethimide, ketoconazole, therapeutic hydrocortisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Early Blood Pressure Management in Extremely Premature Infants

NCT00874393
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Hypotension, Blood Pressure
Interventions
Dopamine, Hydrocortisone, Infusion Placebo, Syringe Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 24 Hours
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 14, 2026, 10:32 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

NCT07494084
View directory record Official record
Conditions
Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment
Interventions
Metyrapone And Hydrocortisone, Dextrose, insulin
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 10:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Stress Hormones on Emotion and Cognition

NCT00032838
View directory record Official record
Conditions
Healthy
Interventions
Yohimbine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 10:32 AM EDT
Completed Phase 3 Interventional

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

NCT00002855
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium, Flutamide, Ketoconazole, Nilutamide, Therapeutic Hydrocortisone, Vinblastine, Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 14, 2026, 10:32 AM EDT